ODM-201
Phase 2Small molecule
Orion Corporation, Orion PharmaODM-201 is one of 29 small molecule programs targeting Prostate Cancer. It is currently in Phase 2.
1
Indications
6
Total Trials
1
Active Trials
28
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
348 competitors in Prostate Cancer
#DrugCompanyPhaseTrials
1Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Antiandrogen Therapy
UUniversity of Washington
Phase 3
AAA817
NovartisPhase 3
Gallium Ga 68 Gozetotide
MMayo Clinic
Phase 3
Androgen Deprivation Treatment
MMedical University of Vienna
Phase 3
Trexall
Jazz PharmaceuticalsPreclinical
Duragesic
CCephalon
Preclinical
Ranexa
MMenarini International Operations Luxembourg SA
Preclinical
Botox
VVitae Pharmaceuticals Inc., an Allergan affiliate
Preclinical
ODM-201
Orion Corporation, Orion PharmaPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Prostate Cancer3 trials
ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer
Active, not recruiting·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT02972060·61 enrolled
Tics1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ODM-201. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details